Siplizumab (Anti-CD2)

Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.
Supplier Selleck Chemicals
Product # A2562
Sku # A2562-1mg*5
Pricing 1mg*5, $790.00
Feedback